During follow-up of thyroid cancer,
A bronchial specimen was positive for Mycobacterium avium infection. CT of the thorax (e), performed at 3-month follow-up, showed partial resolution of bronchiectasis. 131 I is a useful radiopharmaceutical in imaging thyroid cancer; [1] it is well known the possibility to detect 131 I uptake in inflammatory lesions. [2] Moreover, other malignant tumors show 131 I-avid uptake that can be managed by SPECT/CT. [3] Hybrid scanners allowed nuclear medicine physicians to identify diagnostic pitfalls occurring in clinical practice. [4] Similarly, to other reports on this topic, [5, 6] the use of CT with "lung window" allowed to identify diffuse 131 I-avid bronchiectasis in a single diagnostic session, minimizing patient discomfort. The 131 I uptake in bronchiectasis is due to expression of sodium-iodide symporter in secretions. [7] Nuclear medicine physicians should be aware of tracer physiological distribution and pitfalls, to avoid misdiagnosis. Laboratory data, expertise on CT, [8] and hybrid imaging are of the utmost importance.
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